Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IMNM

Immunome Inc

Oct 31 • 11:14AM ET

15.97

-0.01 -0.06 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA NVAX SRPT NTLA CRSP PFE GILD BNTX BEAM

| Held by: VTI IWM XBI IWO VXF SCHA VTWO IDNA IWC VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.09	Insider Own	8.37%	Shs Outstand	87.01M	Perf Week	1.78%
Market Cap	1.39B	Forward P/E	-	EPS next Y	-2.37	Insider Trans	0.07%	Shs Float	79.76M	Perf Month	39.23%
Enterprise Value	1.13B	PEG	-	EPS next Q	-0.57	Inst Own	85.32%	Short Float	19.10%	Perf Quarter	45.84%
Income	-212.39M	P/S	110.41	EPS this Y	57.86%	Inst Trans	8.73%	Short Ratio	12.24	Perf Half Y	80.45%
Sales	12.59M	P/B	5.16	EPS next Y	-12.56%	ROA	-71.69%	Short Interest	15.24M	Perf YTD	50.38%
Book/sh	3.09	P/C	5.19	EPS next 5Y	25.10%	ROE	-81.20%	52W High	17.32 -7.78%	Perf Year	30.90%
Cash/sh	3.08	P/FCF	-	EPS past 3/5Y	-32.63% -38.15%	ROIC	-77.68%	52W Low	5.15 210.09%	Perf 3Y	265.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	79.25%	Volatility	6.33% 7.90%	Perf 5Y	36.03%
Dividend TTM	-	EV/Sales	89.45	EPS Y/Y TTM	59.89%	Oper. Margin	-1513.45%	ATR (14)	1.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.13	Sales Y/Y TTM	16.74%	Profit Margin	-1687.08%	RSI (14)	60.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.13	EPS Q/Q	17.24%	SMA20	3.48%	Beta	1.97	Target Price	24.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	69.84%	SMA50	30.25%	Rel Volume	0.35	Prev Close	15.98
Employees	118	LT Debt/Eq	0.02	Earnings	Aug 06 AMC	SMA200	62.14%	Avg Volume	1.24M	Price	15.97
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.23% 381.82%	Trades		Volume	130,888	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
08:00AM	Loading…
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
10:29AM	Loading…
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
04:05PM	Loading…
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%
04:02PM	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets (Business Wire)
Mar-26-24 08:00AM	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala (Business Wire) +5.79%
08:00AM	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome (GlobeNewswire)
Mar-18-24 05:44AM	Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies (Business Wire)
Mar-07-24 08:00AM	Immunome to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-01-24 08:00AM	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference (Business Wire) +5.17%
Feb-20-24 08:15AM	Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (Business Wire) -10.99%
08:00AM	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (GlobeNewswire)
Feb-16-24 04:05PM	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +14.74%
Feb-13-24 10:38PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire)
04:05PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-07-24 08:34AM	Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up (Zacks) +7.83%
Feb-06-24 09:20AM	Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks (FierceBiotech.com) +36.91%
08:00AM	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (Business Wire)
Feb-05-24 08:00AM	Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.91%
Jan-04-24 08:00AM	Immunome Appoints Phil Roberts as Chief Technical Officer (Business Wire)
Jan-03-24 08:00AM	Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.27%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM
Higgins Jack	Chief Scientific Officer	Mar 27 '25	Option Exercise	1.35	5,200	7,020	18,729	Mar 28 05:54 PM
BIENAIME JEAN JACQUES	Director	Mar 25 '25	Buy	7.78	7,800	60,684	31,415	Mar 26 04:05 PM
SIEGALL CLAY B	President and CEO	Mar 26 '25	Buy	7.29	137,100	999,459	806,736	Mar 26 04:03 PM
BIENAIME JEAN JACQUES	Director	Mar 24 '25	Buy	8.21	7,000	57,470	23,615	Mar 25 05:18 PM
Tsai Philip	Chief Technology Officer	Mar 24 '25	Buy	8.42	12,300	103,566	33,300	Mar 25 05:15 PM
SIEGALL CLAY B	President and CEO	Jan 31 '25	Buy	7.75	150,000	1,162,500	669,636	Feb 03 09:01 PM
SIEGALL CLAY B	President and CEO	Nov 21 '24	Buy	9.54	66,057	630,263	485,693	Nov 25 08:41 AM
SIEGALL CLAY B	President and CEO	Nov 22 '24	Buy	9.78	33,943	331,918	519,636	Nov 25 08:41 AM
Lechleider Robert	Chief Medical Officer	Nov 21 '24	Buy	9.48	15,805	149,800	15,805	Nov 25 08:35 AM
Tsai Philip	Chief Technology Officer	Nov 21 '24	Buy	9.43	21,000	198,030	21,000	Nov 25 08:33 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNM

Immunome Inc

Upgrade your FINVIZ experience